Gsk PLC (GLAXF) SEC Filings — 2024

Filings

• GSK plc Files 6-K for PDMR Shareholding Notification — 6-K · Dec 23, 2024
• GSK's Jemperli Trial Meets Ovarian Cancer Endpoint — 6-K · Dec 20, 2024
• GSK's Jemperli gets EU nod for broader endometrial cancer use — 6-K · Dec 16, 2024
• GSK CEO Emma Walmsley Files Initial Shareholding Notification — 6-K · Dec 12, 2024
• FDA Accepts GSK's Nucala for COPD Treatment — 6-K · Dec 9, 2024
• GSK Extends China Vaccine Deal with Zhifei to 2034 — 6-K · Dec 5, 2024
• GSK plc Reports 3.4B Shares Outstanding Nov 30 — 6-K · Dec 2, 2024
• GSK's Menveo Vaccine Gets EU Approval — 6-K · Nov 27, 2024
• FDA Accepts Blenrep Combo Applications for Multiple Myeloma — 6-K · Nov 25, 2024
• Japan Approves GSK's Arexvy for Adults 50-59 — 6-K · Nov 22, 2024
• GSK's Linerixibat Trial Meets Primary Endpoint for PBC Itch — 6-K · Nov 19, 2024
• GSK plc Amends 13D Filing for 23andMe Holding Co. — SC 13D/A · Nov 15, 2024
• GSK's Blenrep Shows Survival Benefit in Myeloma Trial — 6-K · Nov 14, 2024
• GSK plc 6-K: Six-Monthly Bonus Plan Update — 6-K · Nov 13, 2024
• Gsk PLC SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• GSK plc Announces Provisional 2025 Dividend Dates — 6-K · Nov 12, 2024
• GSK plc Reports Total Voting Rights and Capital — 6-K · Nov 1, 2024
• GSK plc: Director's Associate Transaction Notified — 6-K · Oct 30, 2024
• GSK's Arexvy Shows Broader Protection in Younger Adults — 6-K · Oct 24, 2024
• GSK CEO Emma Walmsley Files Initial Shareholding Notification — 6-K · Oct 17, 2024
• FDA Accepts GSK's Gepotidacin NDA for UTI Treatment — 6-K · Oct 16, 2024
• GSK's Depemokimab Shows Positive Phase III Results for CRSwNP — 6-K · Oct 15, 2024
• GSK CEO Emma Walmsley Files Initial Shareholding Notification — 6-K · Oct 11, 2024
• GSK CEO Emma Walmsley Files Initial Shareholding Notification — 6-K · Oct 10, 2024
• GSK Settles 93% of US Zantac Lawsuits for $2.2B — 6-K · Oct 9, 2024
• GSK's Arexvy RSV Vaccine Shows 3-Season Efficacy — 6-K · Oct 8, 2024
• GSK plc Reports Total Voting Rights as of Sept 30, 2024 — 6-K · Oct 1, 2024
• GSK Menveo Vaccine Gets EU CHMP Green Light — 6-K · Sep 24, 2024
• GSK settles Zantac litigation in California — 6-K · Sep 18, 2024
• GSK's Blenrep Combo Gets Japan Review Nod — 6-K · Sep 17, 2024
• GSK's Blenrep Gets China Breakthrough Therapy Nod — 6-K · Sep 13, 2024
• GSK Flu mRNA Vaccine Shows Positive Phase II Results — 6-K · Sep 12, 2024
• GSK Updates Phase I/II Therapeutic HSV Vaccine Trial — 6-K · Sep 11, 2024
• GSK's Depemokimab Shows 54% Asthma Exacerbation Reduction — 6-K · Sep 9, 2024
• GSK's Nucala Shows Positive Phase III COPD Results — 6-K · Sep 6, 2024
• GSK plc Capital Update: 4B Shares Issued, 1 in Treasury — 6-K · Sep 3, 2024
• EU Approves Expanded Age Use for GSK's RSV Vaccine Arexvy — 6-K · Aug 29, 2024
• GSK's Zantac Litigation Heads to Delaware Supreme Court — 6-K · Aug 28, 2024
• GSK plc Files 6-K for PDMR Shareholding Notification — 6-K · Aug 21, 2024
• GSK's B7-H3 ADC gets FDA Breakthrough Therapy Designation — 6-K · Aug 20, 2024
• GSK Wins Zantac Litigation Ruling in Florida — 6-K · Aug 16, 2024
• GSK plc Files 6-K: PDMR Shareholding Disclosure — 6-K · Aug 12, 2024
• GSK to Appeal $120M Zantac Verdict — 6-K · Aug 6, 2024
• FDA Expands Jemperli Approval for Endometrial Cancer — 6-K · Aug 2, 2024
• GSK Sells Remaining Haleon Stake for $2.1B — 6-K · Aug 1, 2024
• GSK plc Upgrades 2024 Guidance After Strong Q2 Performance — 6-K · Jul 31, 2024
• GSK's Arexvy gets EU nod for 50-59 RSV prevention — 6-K · Jul 29, 2024
• GSK's Blenrep Combo Therapy Under EMA Review — 6-K · Jul 19, 2024
• GSK CEO Emma Walmsley's Shareholding Notified — 6-K · Jul 18, 2024
• GSK CEO Emma Walmsley Reports Shareholding Transaction — 6-K · Jul 16, 2024